High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.03B
+3.59%
2.966
+21.55%
1.01B
+3.52%
2.408
+13.05%
1.05B
+4.03%
2.682
+7.72%
Estimates Revision
The market is revising Upward the revenue expectations for Align Technology, Inc. (ALGN) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by 0.85%.
Revenue Estimates for FY2025
Revise Upward
+0.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.86%
In Past 3 Month
Stock Price
Go Up
+0.85%
In Past 3 Month
11 Analyst Rating
Wall Street analysts forecast ALGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGN is 171.33 USD with a low forecast of 140.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 141.690
Low
140.00
Averages
171.33
High
200.00
Current: 141.690
Low
140.00
Averages
171.33
High
200.00
Evercore ISI
Outperform
maintain
$160 -> $170
2025-10-30
Reason
Evercore ISI
Price Target
$160 -> $170
2025-10-30
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on Align Technology to $170 from $160 and keeps an Outperform rating on the shares after "a strong Q3 performance" with cases up 4.9% year-over-year, topping expectations. A 22c beat on EPS "underlines the effective cost management and operational leverage," the analyst tells investors.
Piper Sandler
Jason Bednar
Overweight
maintain
$190 -> $200
2025-10-30
Reason
Piper Sandler
Jason Bednar
Price Target
$190 -> $200
2025-10-30
maintain
Overweight
Reason
Piper Sandler analyst Jason Bednar raised the firm's price target on Align Technology to $200 from $190 and keeps an Overweight rating on the shares. Shares of Align have been out-of-favor with investors since the Q2 print, in part because of revenue visibility challenges the business had encountered, but also due to an implied Q4 revenue ramp that looked challenging based on historical seasonality, the firm notes. But Q3 cured both of those ills as management delivered broad volume upside in the period, which has the effect of also shortening the putt to hit the originally implied Q4 targets, adds Piper.
UBS
Neutral
downgrade
$160 -> $155
2025-10-16
Reason
UBS
Price Target
$160 -> $155
2025-10-16
downgrade
Neutral
Reason
UBS lowered the firm's price target on Align Technology to $155 from $160 and keeps a Neutral rating on the shares. Shares are down 38% year-to-date and 81% from 2021 highs, trading at a historically low multiple after a weak Q2, the analyst tells investors in a research note. Sentiment remains pressured by share losses to traditional braces and competitors, declining ASPs for Invisalign, soft consumer confidence, limited management visibility, and muted dental demand, factors that have eroded confidence in Align's ability to meet Q3 expectations or maintain full-year guidance, the firm says.
Leerink
Outperform
maintain
$246 -> $248
2025-07-14
Reason
Leerink
Price Target
$246 -> $248
2025-07-14
maintain
Outperform
Reason
Leerink raised the firm's price target on Align Technology to $248 from $246 and keeps an Outperform rating on the shares. Heading into Q2 earnings, the firm is updating dental company estimates and publishing the results of its fourth semi-annual dental survey of 63 dental practitioners in the United States. There is clearly a budding interest in identifying incremental improvements across the dental space, even if each opportunity seems to be company-specific in what remains a still-challenged total dental end-market, Leerink says. The firm sees reasons to be positive on each stock in its coverage but also has some offsetting questions that limit too much constructiveness.
HSBC
Buy
to
Hold
downgrade
$290 -> $170
2025-04-25
Reason
HSBC
Price Target
$290 -> $170
2025-04-25
downgrade
Buy
to
Hold
Reason
HSBC downgraded Align Technology to Hold from Buy with a price target of $170, down from $290. The firm adjusted ratings in medical technology and life sciences are quantifying the risk/reward using stagflation, weak macro environment, and recovery scenario analyses. The market is debating whether the recent multiples correction is an opportunity to buy, or if it is the start of a potential recession, the analyst tells investors in a research note. HSBC's analysis of historical sector multiples reveals that the multiples compression might have an additional 20%-25% downside in a stagflation scenario. "We are far from the point where one can argue that these stocks are pricing in a recession," contends HSBC.
UBS
Neutral
downgrade
$240 -> $215
2025-04-24
Reason
UBS
Price Target
$240 -> $215
2025-04-24
downgrade
Neutral
Reason
UBS lowered the firm's price target on Align Technology to $215 from $240 and keeps a Neutral rating on the shares. While macro concerns are weighing on the stock, increased financing options may drive upside, the analyst tells investors in a research note. The company's May 6 investor day presents a catalyst for the management team to reshape the narrative, set a new, and more realistic, long-term target, and detail the contribution and market opportunity for new offerings, UBS says.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Align Technology Inc (ALGN.O) is 13.12, compared to its 5-year average forward P/E of 35.00. For a more detailed relative valuation and DCF analysis to assess Align Technology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
35.00
Current PE
13.12
Overvalued PE
50.64
Undervalued PE
19.36
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
23.73
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
34.11
Undervalued EV/EBITDA
13.35
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
7.99
Current PS
141.69
Overvalued PS
21.67
Undervalued PS
-5.70
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ALGN News & Events
Events Timeline
(ET)
2025-10-30
09:55:03
Significant Early Gainers in Liquid Options on October 30th
2025-10-29 (ET)
2025-10-29
16:03:57
Align Technology announces Q3 adjusted EPS of $2.61, surpassing consensus estimate of $2.41.
2025-10-29
14:59:41
Prominent Companies Set to Report After Market Close
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/23ded55dc4a26f043bd1a1348ea8ab33034056d2c4beaf253313390eb44bb496.png)
Preview
4.5
11-12BenzingaWall Street Holds Steady as Silver Surges Past $50 Amid Signs of Shutdown Resolution: Market Movers for Tuesday
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/703087d750ba0569fd0e8d71aaa6f7deba1d95bfbe1296a6919c75bff9af4cc2.jpg)
Preview
9.5
11-10NASDAQ.COMWhat Factors Contribute to Boston Scientific's Positive Outlook for Urology Expansion?
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/b4f6474346efacfb67eb72abc5eeccf37d80f649fd4e9cf476de4a1e8639ee15.jpg)
Preview
4.5
10-31NASDAQ.COMStocks Close Down as Major Tech Companies Decline
Sign Up For More News
People Also Watch
FAQ
What is Align Technology Inc (ALGN) stock price today?
What is Align Technology Inc (ALGN)'s business?
What is the price predicton of ALGN Stock?
What is Align Technology Inc (ALGN)'s revenue for the last quarter?
What is Align Technology Inc (ALGN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Align Technology Inc (ALGN)'s fundamentals?
How many employees does Align Technology Inc (ALGN). have?